Amyloidosis Center News
Hematologist on our multidisciplinary clinical team, Dr. Mark Sloan, @jmarksloan, was named as an Evans Outstanding Clinician
We are proud to announce that the hematologist on our multidisciplinary clinical team, Dr. Mark Sloan, @jmarksloan, was named as an Evans Outstanding Clinician. He is being recognized as for clinical skills, attributes and professionalism that define excellence. This award is intended to acknowledge the value of clinical medicine and honor... More
2019 House and Senate language on Amyloidosis
August 24, 2018 Last night the Senate passed the fiscal year 2019 Labor HHS bill. This is the first time the bill has passed the Senate floor in a decade. This gives more emphasis to language included in the Senate and House reports on Amyloidosis and the hope for completing a... More
FDA COULD MAKE A HISTORIC DECISION FOR AMYLOIDOSIS PATIENTS
https://www.xconomy.com/boston/2018/08/03/patients-have-fingers-crossed-as-alnylam-awaits-historic-fda-decision/
Repurposing a cardiac test to help diagnose cardiac transthyretin amyloidosis
Featuring Dr. Frederick L. Ruberg, our senior cardiologist | Read more below https://www.cardiovascularbusiness.com/topics/imaging/resurrecting-tc-99m-pyp-cardiac-amyloidosis-therapies-emerge-old-test-gains-new
Proud to Present Dr. John Berk’s Research in hereditary ATTR Amyloidosis in New England Journal of Medicine
We are proud to announce 2 publications in the New England Journal of Medicine highlighting Dr. John Berk's research in hereditary ATTR amyloidosis. You can find both articles linked below. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis NEJM | PubMed Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis NEJM | PubMed Congratulations to Dr. More
3rd Annual Fit To Be Tied Race Wrap-Up
We would like to give a big shout-out to everyone that came out to the 3rd Annual Fit to Be Tied in support for Amyloidosis, which took place on May 20th, 2018 in Onondaga Lake Park in Liverpool, NY. We would also like to sincerely thank Ms. Floris Palmer and... More
Dr. Alan S. Cohen, founding Director of the Amyloidosis Center, passes away at age 92
It is with the utmost sorrow that we announce the passing of Dr. Alan S. Cohen, the founding director of The Amyloidosis Center. Dr. Cohen established The Amyloidosis Center as well as the first Arthritis section at the Boston University School of Medicine in 1960. His contributions in the clinical... More
Ann Peel Urges the US Congress to Support Amyloidosis Research for 2019
Ann Peel gave her testimony on amyloidosis to the House and Senate Appropriations Committees on April 26th, 2018. The testimony seeks support for Amyloidosis programs from Congress in the fiscal year 2019 Labor, Health Services and Education Appropriations bill. Please see her complete statement below. We are very grateful to Ann and Terry Peel... More
Dr. John Berk Speaks at 2018 AAN Meeting on Phase 3 Inotersen Results in hATTR
This past weekend, Dr. John Berk had the privilege of speaking at the 2018 American Academy of Neurology Annual Meeting in Los Angeles, California. Dr. Berk gave an impressive talk on the phase 3 inotersen results in hATTR to a packed house of neurologists. You can read more about the... More
NEWS: Prothena Discontinues Development of NEOD001 for AL Amyloidosis
On April 23rd, 2018, Prothena Corporation plc announced the discontinuation of the development of NEOD001, an investigational monoclonal antibody targeting circulating soluble and deposited amyloid found in patients with AL Amyloidosis. The decision was made based on results from the Phase 2b PRONTO study and a fuity analysis of the... More